Skip to main content
SpringerLink
Log in

Bisphosphonate Therapy for Postmenopausal Osteoporosis

  • Chapter
Osteoporosis in Clinical Practice

  • 372 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Selected References

  • Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465–73 [discus ses mechanisms of action].

    Article  PubMed  CAS  Google Scholar 

  • Black DM, Thompson DE, Bauer DC, et al. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85(11):4118–4124.

    Google Scholar 

  • Black DM, Greenspan, SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ (2003) PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349(13):1207–15.

    Article  PubMed  CAS  Google Scholar 

  • Bone HG. (2000) Development and Evaluation of New Drugs for Osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds). Osteoporosis, 2nd edn. San Diego: Academic Press, pp. 533–538.

    Google Scholar 

  • Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates J, Lombardi A (2000) Alendronate and estrogen effects on post-menopausal women with low bone mineral density. Alendronate and estrogen effects on post-menopausal women with low bone mineral density 85(2): 720–6.

    Google Scholar 

  • Bone H, Hosking D, Devogelaer JP, Tucci R, Emkey R, Tonino R, Rodriguez-Portales JA, Downs R, Gupta J, Santora A, Liberman U (2004) For the Alendronate Phase III Osteoporosis Treatment Study Group; Ten year experience with alendronate in the treatment of postmenopausal osteoporotic women. For the Alendronate Phase III Osteoporosis Treatment Study Group; Ten year experience with alendronate in the treatment of postmenopausal osteoporotic women 350:1189–1199.

    Google Scholar 

  • Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer R, Delmas PD (2004) for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe. J Bone Miner Res (in press).

    Google Scholar 

  • Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroidinduced bone loss: a twelve-month, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthritis Rheum 42(11):2309–2318.

    Article  PubMed  CAS  Google Scholar 

  • Committee for Proprietary Medicinal Products (CPMP) Efficacy Working Party. Note for Guidance on Involutional Osteoporosis in Women. 1999; CPMP/EWP/552/95. Available via http://emea.eu.int/htms/human/ewp/ewpfin.html

    Google Scholar 

  • Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J Bone Miner Res 13(6):1051–1055.

    Article  PubMed  CAS  Google Scholar 

  • Cummings SR, Palermo L, Browner W, et al. (2000) Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283(10):1318–1321.

    Google Scholar 

  • Eastell R. (2000) Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 237(5):439–447.

    Article  Google Scholar 

  • Ensrud KE, Black DM, Palermo L, et al. (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157(22):2617–2624.

    Google Scholar 

  • Food and Drug Administration (FDA). Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Issued April 1994. Available via http://www.fda.gov/cder/guidance/index.htm

    Google Scholar 

  • Frost HM (1979) Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop 143:227–244.

    PubMed  Google Scholar 

  • Garnero P, Delmas PD (1996) New developments in biochemical markers for osteoporosis. Calcif Tissue Int 59 Suppl 1:S2–9.

    Article  Google Scholar 

  • Harris ST, Watts NB, Genant HK, et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352.

    Google Scholar 

  • Harris ST, Watts NB, Jackson RD, et al. (1993) Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 95(6):557–567.

    Google Scholar 

  • Krieg M.A., Gillard-Berquer D, Comuz J., Burckhardt P., Gov J.J., Thiebaud D (1998) Intravenous pamidronate as treatment of osteoporosis after heart transplantation. Osteoporos Int 8(Suppl 3):114.

    Google Scholar 

  • McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–40.

    Article  PubMed  CAS  Google Scholar 

  • Nevitt MC, Ross PD, Palermo L, Musliner T, Genant HK, Thompson DE (1999) Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group. Bone 25(5):613–619.

    Article  PubMed  CAS  Google Scholar 

  • Orwoll E, Ettinger M, Weiss S, et al. (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343(9):604–610.

    Google Scholar 

  • Recker R, Stakkestad J, Chesnut C, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer R, Delmas P (2004) Clinical assessment of intravenous ibandronate injection once every 3 months in postmenopausal osteoporosis. Bone (in press)

    Google Scholar 

  • Reeves HL, Francis RM, Manas DM, Hudson M, Day CP (1998) Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4(5):404–409.

    Article  PubMed  CAS  Google Scholar 

  • Reginster J, Minne HW, Sorensen OH, et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1): 83–9.

    Google Scholar 

  • Reid JR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Iaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier P (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346(9):653–61.

    Article  PubMed  CAS  Google Scholar 

  • Reszka AA, Halasy-Nagy J, Rodan GA (2001) Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 59(2):193–202.

    PubMed  CAS  Google Scholar 

  • Rittmaster RS, Bolognese M, Ettinger MP, et al. (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85(6):2129–2134.

    Google Scholar 

  • Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32): 2643–58

    Article  PubMed  CAS  Google Scholar 

  • Saag KG, Emkey R, Schnitzer TJ, et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292–299.

    Google Scholar 

  • Schnitzer T, Bone HG, Crepaldi G, et al. (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 12(1):1–12.

    Google Scholar 

  • Watts NB (2001) Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am 27(1):197–214.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Henry Bone
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag London

About this chapter

Cite this chapter

Bone, H. (2004). Bisphosphonate Therapy for Postmenopausal Osteoporosis. In: Osteoporosis in Clinical Practice. Springer, London. https://doi.org/10.1007/978-0-85729-402-9_17

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-402-9_17

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-757-5

  • Online ISBN: 978-0-85729-402-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation